AstraZeneca in Talks to Buy Bristol Myers Squibb in $400B Pharma Megadeal

AstraZeneca (AZN) has been in talks with Bristol Myers Squibb (BMY) about a potential merger that would create a combined company valued at nearly $400 billion, the Financial Times reported on August 2, 2026, citing people familiar with the matter. AstraZeneca declined to comment. Bristol Myers did not respond to requests for comment. The report cautioned that a deal could materialize soon or fall apart entirely.

AZN stock closed at $169.64 on Friday, August 1. BMY closed at $65.31, near its 52-week high of $65.66 and up roughly 44% over the past year. The combined market capitalization of the two companies is approximately $400 billion.

Monday update August 4, 2026: AZN shares fell 6.9% to $157.97 on Monday August 3 (Polygon) as investors punished the stock on merger concerns. BMY rose slightly to $65.47 (Polygon). CNBC reported that analysts were broadly skeptical, with one calling the deal “a surprising strategic move for one of the pharmaceutical industry’s strongest growth stories.” Reuters confirmed the talks via a person familiar with the matter. AstraZeneca’s U.K.-listed shares were also down on the London Stock Exchange. The combined market value at Monday’s close was approximately $396 billion.

Why AstraZeneca wants Bristol Myers

AstraZeneca CEO Pascal Soriot, who famously rebuffed Pfizer’s $118 billion takeover attempt in 2014, is now the aggressor. Under Soriot’s 14-year tenure, AstraZeneca’s stock has more than quadrupled, driven by an oncology franchise that generated about $25 billion in 2025 sales. Second-quarter results reported July 27 showed continued strong demand for cancer and rare disease drugs.

A Bristol Myers acquisition would give AstraZeneca a deeper U.S. footprint. The company has already announced a $50 billion U.S. manufacturing and R&D commitment and plans for a direct U.S. listing while retaining its London listing.

Why Bristol Myers might sell

Bristol Myers faces a patent cliff. Its two top sellers, blood thinner Eliquis and cancer immunotherapy Opdivo, could lose exclusivity by 2028. Together those products account for roughly half of BMY sales. The company bought Celgene for $80 billion in 2019 to acquire Revlimid, which has already lost patent protection.

Bristol Myers has been filling the gap with newer drugs. The company raised its full-year revenue and profit forecast on July 30 after strong Q2 results. Promising pipeline assets include experimental blood thinner milvexian, anemia treatment Reblozyl, heart drug Camzyos, and CELMoDs iberdomide and mezigdomide in oncology. Cobenfy, BMY’s schizophrenia drug, is also expanding into new indications, though recent delays have pushed some readouts into 2027.

The antitrust problem

The most obvious obstacle is antitrust. Both companies have large, directly competing cancer drug franchises. AstraZeneca’s oncology portfolio includes Enhertu, Tagrisso, and Imjudo. Bristol Myers sells Opdivo, Opdualag, and Yervoy. Oncology accounted for over 40% of each company’s sales in the first half of 2026. A combined entity would face simultaneous scrutiny from the U.S. FTC, the UK CMA, and the European Commission, with overlapping checkpoint inhibitors and ADCs the most likely divestiture candidates.

Large pharma mergers have been rare since 2020, partly because of antitrust enforcement and U.S. pressure on drug pricing. The last major deal was AbbVie’s acquisition of Allergan in 2020.

What to watch

This is a report, not a confirmed deal. The FT said talks have been ongoing for months and could still dissolve. Watch for official confirmations from either company, FTC signals, and how markets price the odds when U.S. trading opens Monday. For context on recent biotech M&A, see J&J’s $3.37B Sail Biomedicines deal and AstraZeneca’s own oncology readouts.